APOL1-Mediated Kidney Disease (AMKD)
MAZEMaze TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for MZE829 (APOL1 Inhibitor) in APOL1-Mediated Kidney Disease (AMKD). The expected timing is based on the latest available company guidance and may change.
03/25/26:- Positive Ph2 HORIZON topline data in AMKD; plan pivotal program, timing TBA. 35.6% uACR drop at week 12; well-tolerated. 05/12/26:- Additional Ph2 HORIZON data expected Q4 2026; pivotal AMKD trial initiation planned H1 2027. 08/11/26:- HORIZON enrollment continues; updated data late 2026 or early 2027, pivotal trial H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.